Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 3;6(23):15168-15181.
doi: 10.1021/acsomega.1c01411. eCollection 2021 Jun 15.

Deferoxamine-Modified Hybrid Materials for Direct Chelation of Fe(III) Ions from Aqueous Solutions and Indication of the Competitiveness of In Vitro Complexing toward a Biological System

Affiliations

Deferoxamine-Modified Hybrid Materials for Direct Chelation of Fe(III) Ions from Aqueous Solutions and Indication of the Competitiveness of In Vitro Complexing toward a Biological System

Mateusz Pawlaczyk et al. ACS Omega. .

Abstract

Deferoxamine (DFO) is one of the most potent iron ion complexing agent belonging to a class of trihydroxamic acids. The extremely high stability constant of the DFO-Fe complex (log β = 30.6) prompts the use of deferoxamine as a targeted receptor for scavenging Fe(III) ions. The following study aimed at deferoxamine immobilization on three different supports: poly(methyl vinyl ether-alt-maleic anhydride), silica particles, and magnetite nanoparticles, leading to a class of hybrid materials exhibiting effectiveness in ferric ion adsorption. The formed deferoxamine-loaded hybrid materials were characterized with several analytical techniques. Their adsorptive properties toward Fe(III) ions in aqueous samples, including pH-dependence, isothermal, kinetic, and thermodynamic experiments, were investigated. The materials were described with high values of maximal adsorption capacity q m, which varied between 87.41 and 140.65 mg g-1, indicating the high adsorptive potential of the DFO-functionalized materials. The adsorption processes were also described as intense, endothermic, and spontaneous. Moreover, an exemplary magnetically active deferoxamine-modified material has been proven for competitive in vitro binding of ferric ions from the biological complex protoporphyrin IX-Fe(III), which may lead to a further examination of the materials' biological or medical applicability.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
(a) Structures of the synthesized deferoxamine-functionalized hybrid materials; (b) formation of the Fe(III)–deferoxamine complex.
Figure 2
Figure 2
(a) FT-IR spectra of the adsorptive materials with indicated specific bands: ν1 = 1051 cm–1; ν2 = 1570 cm–1; ν3 = 1640 cm–1; ν4 = 1705 cm–1; ν5 = 2855 cm–1; ν6 = 2930 cm–1; (b) the thermogravimetric curves obtained during thermal analysis of the materials.
Figure 3
Figure 3
SEM images (A–C) and EDX–SEM mapping of Fe(III) ions (F–H) adsorbed to the hybrid materials: (A, F) PMVEAMA–DFO; (B, G) SiO2–NCO–DFO; (C, H) SiO2–maleimide–DFO). SEM images of magnetite-based hybrid materials: (D) Fe3O4/SiO2–NCO–DFO; (E) Fe3O4/SiO2–maleimide–DFO). Fe is visualized in orange.
Figure 4
Figure 4
Influence of the solution pH on the amount of Fe(III) ions adsorbed on the deferoxamine-functionalized hybrid materials (gray dotted line corresponds to the pH of 5 mM aqueous solution of Fe(ClO4)3 – 2.45).
Figure 5
Figure 5
Fitting of the experimental data to the Langmuir isotherm model.
Figure 6
Figure 6
Experimental data fitting to kinetic models: (a) pseudo–second–order; (b) intraparticle diffusion.
Figure 7
Figure 7
Plots of the van’t Hoff equation fitted to the thermodynamic studies of ferric ion adsorption on the hybrid materials.
Figure 8
Figure 8
Positive ESI–MS spectra: (a) the formed PPIX–Fe complex; (b) PPIX–Fe complex interaction with pure deferoxamine; (c) PPIX–Fe complex interaction with deferoxamine-loaded Fe3O4-based hybrid material 3a.

References

    1. Rassu G.; Salis A.; Porcu E. P.; Giunchedi P.; Roldo M.; Gavini E. Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases. Carbohydrate Polym. 2016, 136, 1338–1347. 10.1016/j.carbpol.2015.10.048. - DOI - PubMed
    1. Li Y.; Yang H.; Ni W.; Gu Y. Effects of deferoxamine on blood–brain barrier disruption after subarachnoid hemorrhage. PLoS One 2017, 12, e017278410.1371/journal.pone.0172784. - DOI - PMC - PubMed
    1. Lane D. J.; Mills T. M.; Shafie N. H.; Merlot A. M.; Moussa R. S.; Kalinowski D. S.; Kovacevic Z.; Pichardson D. R. Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial – mesenchymal transition. Biochem. Biophys. Acta 2014, 1845, 166–181. 10.1016/j.bbcan.2014.01.005. - DOI - PubMed
    1. Hider R. C.; Zhou T. The design of orally active iron chelators. Ann. N. Y. Acad. Sci. 2005, 1054, 141–154. 10.1196/annals.1345.017. - DOI - PubMed
    1. Cozar O.; Leopold N.; Jelic C.; Chis V.; David L.; Mocanu A.; Tomoaia–Cotis M. IR, Raman and surface–enhanced Raman study of desferrioxamine B and its Fe(III) complex, ferrioxamine B. J. Mol. Structure 2006, 788, 1–6. 10.1016/j.molstruc.2005.04.035. - DOI